IQV stock forecast, quote, news & analysis
Iqvia is a global leader in clinical research and technology solutions for the life science industry... Show more
IQVIA Holdings (IQV) Stock Analysis: Accelerating Bookings and AI Adoption Extend the Rebound
Key Takeaways
- IQV shares closed at $270.37, up roughly 3.4% over the trailing 30 days, extending a multi-month climb from the mid-$170s reached in June.
- Second-quarter 2026 results beat expectations, with revenue of $4.37 billion (up 8.7% year over year) and adjusted diluted EPS of $3.15.
- Company-wide organic growth accelerated to 6% year over year — about three times the rate reported a year earlier.
- R&D Solutions net new bookings rose about 19% year over year to $3.15 billion, supporting a book-to-bill ratio of 1.22 and a backlog of roughly $34.2 billion.
- Management raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, citing broad-based demand and AI traction.
Current Market Snapshot
IQVIA Holdings has traded with an upward bias through late summer and into autumn, with the stock consolidating in the upper $250s to low $270s range after a sharp advance following its second-quarter earnings release. The shares have gained about 3.4% over the last 30 days, a modest near-term move that masks a substantially stronger multi-month trend: the stock has risen roughly 40% since late June, reflecting improving sentiment toward the life-sciences services sector and the company's accelerating bookings momentum.
Sector positioning remains a key part of the story. As a leading clinical research organization (CRO) and healthcare data provider, IQVIA sits at the intersection of pharmaceutical R&D outsourcing, real-world data, and applied artificial intelligence. Investors view the company as a leveraged way to gain exposure to biotech funding recovery and increased outsourcing by large pharmaceutical sponsors, balanced against sensitivity to trial pricing and foreign-exchange fluctuations.
IQVIA Holdings (IQV) Business Overview and Competitive Position
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights, and healthcare intelligence to the life-sciences and healthcare industries. With approximately 93,000 employees across more than 100 countries, the company supports biotech, pharmaceutical, and medical-device clients in developing and commercializing treatments.
Effective January 1, 2026, IQVIA simplified its reporting structure into two primary segments: R&D Solutions, which encompasses clinical trial management and related research services, and Commercial Solutions, which includes technology, analytics, real-world insights, and patient-engagement offerings. The company's competitive strengths include its scale, proprietary data assets delivered through its Connected Intelligence platform, and its Healthcare-grade AI capabilities, which emphasize privacy, regulatory compliance, and patient safety. Investors follow IQV closely because its performance serves as a barometer for global pharmaceutical R&D spending and the broader adoption of data-driven healthcare analytics.
Recent Developments Driving IQV
The most significant catalyst in recent weeks was IQVIA's second-quarter 2026 report, released on July 28. The company delivered revenue of $4.37 billion, above consensus estimates of roughly $4.30 billion, while adjusted diluted EPS of $3.15 exceeded expectations. Adjusted EBITDA reached $994 million. Management described the quarter as broad-based, with organic growth accelerating to 6% and stronger operational execution across both business segments.
Bookings provided a particularly encouraging signal. R&D Solutions net new bookings of $3.15 billion represented a roughly 19% year-over-year increase, driving a book-to-bill ratio of 1.22 and extending twelve-month net new bookings to about $11.3 billion. On the back of these results, the company raised its full-year 2026 outlook to revenue of $17.275 billion to $17.475 billion, adjusted EBITDA of $4.00 billion to $4.05 billion, and adjusted diluted EPS of $12.80 to $13.00.
Artificial intelligence has become a recurring theme in management commentary. The company has emphasized healthcare-grade AI agents, expanded analytics and consulting pipelines, and collaboration with technology leaders such as NVIDIA on platforms designed to accelerate trial execution and analytics. Management has argued that AI adoption is creating incremental demand rather than displacing services. A more supportive funding environment for emerging biopharma companies, together with a rising number of new drug launches, has also underpinned demand.
Trending AI Robots
Investors seeking a systematic approach to market analysis can explore Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers across various strategies, timeframes, and performance metrics. Rather than displaying every available bot, the Trending AI Robots section curates only the top-performing and most relevant bots, helping users quickly identify strategies that are currently standing out. Because each bot is built around different technical patterns and holding periods, the page offers a practical way to compare approaches and observe how automated systems interpret changing market conditions. For those interested in data-driven trading tools, the Trending AI Robots page provides a useful starting point.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will shape IQVIA's trajectory through the remainder of 2026. The pace of R&D Solutions bookings and backlog conversion remains the most important demand indicator, given that newly awarded contracts convert to revenue over multiple years. Analysts will also monitor the monetization of AI-enabled offerings across both clinical and commercial segments, along with the integration of recent acquisitions.
On the financial side, investors should track adjusted EBITDA margin progression, foreign-exchange effects, and the company's leverage position, which management has been working to manage alongside ongoing share repurchases. Macro-level risks include potential shifts in biotech funding, pricing pressure in the competitive CRO market, and regulatory developments affecting pharmaceutical research and reimbursement. IQVIA's next quarterly report is expected in early November, and its updated guidance will offer a clearer view of whether the recent momentum in bookings and organic growth can be sustained.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IQV's Stochastic Oscillator is remaining in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 189 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
IQV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 121 of 229 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.
Bearish Trend Analysis
The 10-day RSI Indicator for IQV moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 30 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IQV as a result. In 51 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for IQV turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 25 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.225) is normal, around the industry mean (72.578). P/E Ratio (33.703) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties